%0 Journal Article
%A Lopez-Lopez, Pedro
%A Frias, Mario
%A Camacho, Angela
%A Machuca, Isabel
%A Caballero-Gomez, Javier
%A Risalde, Maria A
%A Garcia-Bocanegra, Ignacio
%A Perez-Valero, Ignacio
%A Gomez-Villamandos, Jose C
%A Rivero-Juarez, Antonio
%A Rivero, Antonio
%T Seroreversion of IgG anti-HEV in HIV cirrhotic patients: A long-term multi-sampling longitudinal study.
%D 2022
%U http://hdl.handle.net/10668/20022
%X The aim of our study was to evaluate HEV antibody kinetics in HIV/HCV-coinfected patients with cirrhosis. A longitudinal retrospective study was designed. Patients were followed up every 6 months; anti-HEV IgG and IgM antibodies levels and HEV-RNA by qPCR were analysed. The prevalence and incidence of every HEV infection marker were calculated. The kinetics of anti-HEV IgG and IgM during the follow-up were evaluated. Seventy-five patients comprised the study population. The seroprevalence observed was 17.3%. None showed IgM antibodies or HEV-RNA at baseline. None showed detectable HEV viral load during the study period. After a median follow-up of 5.1 years, two of 62 seronegative patients (3.2%) seroconverted to IgG antibody. The incidence for IgM was 2.7%. Of the 13 patients with IgG seropositivity at baseline, five (38.5%) seroreverted. Meanwhile, of the two patients who exhibited IgM positivity during the study, one (50%) showed intermittent positivity. We found that HEV seropositivity is common in HIV/HCV-coinfected cirrhotic patients. A remarkable rate of IgG seroreversions and IgM intermittence was found, limiting the use of antibodies for the diagnosis of HEV infection in this population.
%K HCV
%K HEV
%K HIV
%K Antibodies
%K Cirrhotic
%K Seroreversion
%~